Inventor
GLASS DAVID J
US16 patents
⚠️ This page may combine multiple inventors who share the name “GLASS DAVID J”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
REGENERON PHARMA
10 patentsUS7355018B2Apr 8, 2008
Modified IGF1 polypeptides with increased stability and potency
REGENERON PHARMA42 citations95
US7396918B2Jul 8, 2008
IGF-I fusion polypeptides and therapeutic uses thereof
REGENERON PHARMA14 citations92
US6852838B2Feb 8, 2005
Tyrosine kinase receptors and ligands
REGENERON PHARMA15 citations92
US5814478ASep 29, 1998
Tyrosine kinase receptors and ligands
REGENERON PHARMA20 citations92
US7837999B2Nov 23, 2010
Method of increasing muscle mass with IGF-1 fusion polypeptides
REGENERON PHARMA11 citations84
US7521211B2Apr 21, 2009
IGF-1 and IGF-2 chimeric polypeptides and therapeutic uses thereof
REGENERON PHARMA12 citations83
US6413740B1Jul 2, 2002
Tyrosine kinase receptors and ligands
REGENERON PHARMA7 citations74
US7781404B2Aug 24, 2010
IGF-1 and IGF-2 chimeric polypeptides and therapeutic uses thereof
REGENERON PHARMA5 citations73
US7632503B2Dec 15, 2009
Method of treating a muscle-related condition with modified IGF1 polypeptides
REGENERON PHARMA7 citations72
US7122648B2Oct 17, 2006
Ion channel receptor and uses thereof
REGENERON PHARMA0 citations51
GLASS DAVID J
2 patentsNOVARTIS AG
2 patentsUS10982000B2Apr 20, 2021
Methods for treating and/or reducing the likelihood of heart failure by administering anti-activin receptor type II (anti-ActRII) antibody
NOVARTIS AG2 citations67
US11834508B2Dec 5, 2023
Method of treating structural and/or functional cardiac abnormalities by administering an anti-ActRII receptor antibody
NOVARTIS AG0 citations56